Magee Thomson Investment Partners’s Abeona Therapeutics ABEO Stock Holding History

Magee Thomson Investment Partners’s Portfolio ABEO Stock Details ABEO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	$1K	Buy	+5	New	+$645	﹤0.01%	29

Other funds holding ABEO

Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return

Adage Capital Partners

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Soros Fund Management New York $9.12B AUM 30.69% 1-Year Est. Return

Castle Hook Partners New York $23.4B AUM 158.96% 1-Year Est. Return

Highbridge Capital Management New York $3.09B AUM 31.19% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Nexthera Capital New York $120M AUM 10.01% 1-Year Est. Return

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Magee Thomson Investment Partners's ABEO Position: Q1 2017 in Review

Magee Thomson Investment Partners opened a new position in Abeona Therapeutics (ABEO) in Q1 2017: 5 shares worth $1K. The stake represents ﹤0.01% of the portfolio and ranks #29 among its holdings.

58 funds tracked by Wall St. Rank hold ABEO as of Q1 2017.

Magee Thomson Investment Partners held 5 shares of Abeona Therapeutics worth $1K as of Q1 2017.
Abeona Therapeutics was a new Magee Thomson Investment Partners position in Q1 2017.
Abeona Therapeutics made up ﹤0.01% of Magee Thomson Investment Partners's portfolio in Q1 2017, its #29 holding.
58 funds tracked by Wall St. Rank held Abeona Therapeutics as of Q1 2017.

Based on Magee Thomson Investment Partners's 13F filing for Q1 2017, filed 21 Apr 2017.